乳清酸镁 | 34717-03-8

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 乳清酸镁
• 英文名称: magnesium;2,4-dioxo-1H-pyrimidine-6-carboxylic acid;2-oxido-6-oxo-1H-pyrimidine-4-carboxylate
• CAS: 34717-03-8
• 化学式: C10H6MgN4O8
• 分子量: 334.48
• InChiKey: QWLHYYKDLOVBNV-UHFFFAOYSA-L

物化性质

• LogP：
  -0.928 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  -5.53
• 重原子数：
  23
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  197
• 氢给体数：
  4
• 氢受体数：
  8

安全信息

• 危险等级：
  IRRITANT

制备方法与用途

用途：中间体

文献信息

• PREPARATIONS CONTAINING AMINO ACIDS AND OROTIC ACID
  申请人：MacDougall Joseph

  公开号：US20090156812A1

  公开（公告）日：2009-06-18

  The present invention describes compounds produced from an orotic acid molecule and an amino acid molecule. The compounds being in the form of amino acid orotate compounds bound by an amide linkage and produced by one of two disclosed methods; 1) reacting orotic acid or derivatives thereof with a thionyl halide, and then combining the acyl halide with an amino acid in the presence of dichloromethane and a DMAP catalyst; or 2) protecting the carboxylic acid of an amino acid and then combining the amino acid with a DCC activated orotic acid, followed by removal of the carboxylic acid protecting group. The resulting amino acid orotate amide has an enhanced stability in solution as compared to a related ester. In addition, specific benefits are conferred by the particular amino acid used to form the compounds in addition to, and separate from, the orotate substituent.

  本发明描述了从乳酸和氨基酸分子产生的化合物。这些化合物以氨基酸乳酸盐的形式存在，通过酰胺键结合，并通过两种方法之一制备：1）将乳酸或其衍生物与硫酰卤反应，然后在二氯甲烷和DMAP催化剂的存在下将酰卤与氨基酸结合；或2）保护氨基酸的羧基，然后将氨基酸与DCC活化的乳酸结合，随后去除羧基保护基团。与相关酯相比，所得的氨基酸乳酸酰胺在溶液中具有更高的稳定性。此外，特定的氨基酸用于形成这些化合物，除了乳酸取代基外，还赋予了特定的益处。
• [EN] PREPARATIONS CONTAINING AMINO ACIDS AND OROTIC ACID<br/>[FR] PRÉPARATIONS CONTENANT DES ACIDES AMINÉS ET DE L'ACIDE OROTIQUE
  申请人：IOVATE T & P INC

  公开号：WO2009076743A1

  公开（公告）日：2009-06-25

  The present invention describes compounds produced from an orotic acid molecule and an ammo acid molecule The compounds, which include an amide linkage, are represented by the general Formula (I), wherein R is selected from the group consisting of (CH3)2CHCH2-, (CH3)2CH-, CH3CH2CH(CH3)-, H2NC(=NH)NH(CH2)3-, and C6H5CH2- Formula (I). The compounds are produced by one of two disclosed methods 1) reacting orotic acid or derivatives thereof with a thionyl halide, and then combining the acyl halide with an ammo acid in the presence of dichloromethane and a dimethylammopyπdme (DMAP) catalyst, or 2) protecting the carboxylic acid of an ammo acid with a benzyl group, and then combining the benzyl-protected ammo acid with a dicyclohexylcarbodiimide (DCC) activated orotic acid, followed by removal of the protecting group. The resulting ammo acid orotate amide compounds are aimed at providing enhanced stability in solution compared with the related esters.

  该发明描述了由乳酸分子和氨基酸分子产生的化合物。这些化合物包括酰胺键，由通用式(I)表示，其中R选自(CH3)2CH -、( )2CH-、 CH( )-、H2NC(=NH)NH(CH2)3-和C6H5 -。这些化合物由两种方法之一制备：1）将乳酸或其衍生物与硫酰卤反应，然后在二氯甲烷和二甲基氨基吡啶(DMAP)催化剂存在下将酰卤与氨基酸结合；2）用苄基保护氨基酸的羧基，然后将苄基保护的氨基酸与二环己基碳二亚胺（DCC）活化的乳酸结合，然后去除保护基。最终产生的氨基酸乳酸酰胺化合物旨在在溶液中提供比相关酯更强的稳定性。
• Process for preparing a creatine heterocyclic acid salt and method of use.
  申请人：——

  公开号：US20040198823A1

  公开（公告）日：2004-10-07

  This invention relates to a process for the synthesis and method of use of an effective amount of a creatine heterocyclic acid salt for the regulation athletic function in humans.

  这项发明涉及一种用于合成和使用一种有效量的肌酸杂环酸盐的方法，用于调节人类的运动功能。
• Pharmaceutical composition and method for the transdermal delivery of magnesium
  申请人：Brierre T. Barbara

  公开号：US20050196433A1

  公开（公告）日：2005-09-08

  The present invention relates to a method and transdermal pharmaceutical composition for preventing magnesium deficiency or imbalances associated with magnesium deficiency including diabetes, hypertension, high cholesterol, cardiac arrhythmias, acute myocardial infarction, arteriosclerosis, atherosclerosis, preeclampsia, dysautonomia, mitral valve prolapse, asthma, constipation, irritable bowel syndrome, migraines, muscle spasms and cramping, premenstrual syndrome, osteoporosis, kidney stones, chronic fatigue syndrome, and fibromyalgia. The transdermal pharmaceutical composition includes a therapeutically effective amount of a pharmaceutically acceptable salt of magnesium and a pharmaceutically acceptable carrier. A therapeutically effective amount of a pharmaceutically acceptable salt of zinc or a vitamin such as vitamin B 6 or vitamin B 12 , or a combination thereof may also be included in the transdermal pharmaceutical composition. A therapeutically effective amount of progesterone may also be included in the transdermal pharmaceutical composition. The transdermal pharmaceutical composition may be topically administered to prevent magnesium deficiency or imbalances caused by magnesium deficiency.

  本发明涉及一种方法和经皮药物组成物，用于预防与镁缺乏有关的镁缺乏或不平衡，包括糖尿病、高血压、高胆固醇、心律失常、急性心肌梗死、动脉硬化、动脉粥样硬化、先兆子痫、自主神经功能失调、二尖瓣脱垂、哮喘、便秘、肠易激综合征、偏头痛、肌肉痉挛和抽筋、经前综合征、骨质疏松症、肾结石、慢性疲劳综合征和纤维肌痛。经皮药物组成物包括治疗有效量的镁的药用盐和药用载体。经皮药物组成物中还可以包括治疗有效量的锌的药用盐或维生素，如维生素B6或维生素B12，或其组合。经皮药物组成物中还可以包括治疗有效量的孕酮。经皮药物组成物可以局部应用以预防由镁缺乏引起的镁缺乏或不平衡。
• PROTEIN BEVERAGE AND METHOD OF MAKING THE SAME
  申请人：Sherwood Shawn

  公开号：US20070148305A1

  公开（公告）日：2007-06-28

  An improved protein beverage/drink composition which may provide a relatively high protein content, ranging from about 0.01% by weight to about 15% by weight, while optionally employing a carbonation concentration between about 0.1 volumes of carbonation (per volume of liquid drink solution or liquid drink suspension) to about 6 volumes of carbonation. Preferably the protein is a protein, such preferably as whey protein, or others. The protein beverage may contain juice and/or an additive which provides energy generation enhancement. The protein beverage may be heat treated to inactivate pathogenic microbes in the presence of the carbonation which may be used to provide taste and mouth feel for the drink. Typically, the treatment for pathogenic microbe inactivation is carried out in the individual package used for storage and handling of the protein drink.

  一种改进的蛋白饮料/饮品配方，可提供相对较高的蛋白质含量，范围从约0.01%重量到约15%重量，同时可选择使用约0.1体积碳酸化浓度至约6体积碳酸化。最好的蛋白质是蛋白质，例如乳清蛋白或其他蛋白质。蛋白饮料可以含有果汁和/或提供能量增强的添加剂。蛋白质饮料可以经过热处理，在碳酸化的情况下灭活致病微生物，这可用于提供饮料的口感和口感。通常，在用于存储和处理蛋白质饮料的个别包装中进行致病微生物灭活处理。